and Sustainable Solutions.
At Versani Health Consulting, we are experts in offering strategic solutions for the Life Sciences industry and the Healthcare sector. We are by your side in a solid partnership, focused on achieving consistent and impactful results.
We understand the complexity and constant transformations of this crucial sector. That’s why we work collaboratively, immersed in the context and needs of our clients, to develop customized, creative and sustainable solutions. Our commitment is to transform these solutions into successful long-term strategies.
We operate with a focus on concrete results, based on rigorous ethical practices and full compliance with the best compliance policies, ensuring that our actions always reflect integrity and
Our Solutions
Specialized Consulting in Business Strategies:
Choosing the right approach to the healthcare market and the most perfect business model is essential for the introduction, growth and development of the business in a sustainable way.
Launch of new Health Technologies:
Market access:
Product Positioning:
Go-To-Market / Distribution / Partnership Models:
Our Team
Versani Health Consulting is led by two highly experienced professionals who, throughout their extensive careers, have led businesses in Brazil and other Latin American countries for the most important and respected pharmaceutical companies in the world:
Maurício Quintas Grimoni
Since 2012, as founder and senior consultant at Latina Health Solutions and since 2018, as founder and senior consultant at Versani Health Consulting, he has led consulting projects for important pharmaceutical and consulting companies specialized in the Life Sciences industry and the Healthcare Sector in Brazil and other Latin American countries.
Continue reading…
Orlando Vitor Silva
He began his career in 1976 at the American company West Pharmaceutical Services, leaving the company in 1996 as Industrial Manager. Between 1996 and 2006, he worked at the Swiss pharmaceutical company Serono, a leading pharmaceutical company in the development of biological and biotechnological medicines for Human Reproduction and Multiple Sclerosis, where he held the position of Corporate Director until the company was incorporated by the German company Merck. At Merck, he worked directly in the merger of the two companies, supporting the creation of the Merck Serono unit, with responsibilities as Regulatory, Corporate and Access Director.
From 2013 to 2023 he worked as an executive at Eli Lilly do Brasil, leaving the company in March 2023 as Associate Vice President of Corporate Affairs, responsible for Regulatory, Market Access, Government Relations and Communication.
Until 2020, he served as an ad-hoc member of Anvisa on the review committee of the Brazilian Pharmacopoeia of Biological Products, and since 2004 he has been a Professor in the Postgraduate Program at Faculdade Oswaldo Cruz, in the chair of Registration of Biological/Biotechnological Products.
Continue reading…